{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:18Z","timestamp":1792036878154,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Anacor Pharmaceuticals, Inc"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly & Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kadmon Corporation, LLC"},{"name":"LEO Pharma"},{"name":"MedImmune, LLC"},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharmaceutical Industries Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Valeant Pharmaceuticals"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"name":"Janssen"},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vitae"},{"name":"Glenmark"},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asana"},{"name":"Innovaderm"},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jaad.2019.12.028","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T11:20:31Z","timestamp":1576840831000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways"],"prefix":"10.1016","volume":"83","author":[{"given":"Michelle S.","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianni","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Sanz-Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Renert-Yuval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2019.12.028_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0190-9622(80)80181-2","article-title":"Granuloma annulare","volume":"3","author":"Muhlbauer","year":"1980","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.028_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2015.03.054","article-title":"Granuloma annulare: clinical and histologic variants, epidemiology, and genetics","volume":"75","author":"Piette","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.028_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0190-9622(89)70005-0","article-title":"Generalized granuloma annulare: clinical and laboratory findings in 100 patients","volume":"20","author":"Dabski","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40257-013-0029-5","article-title":"Etiology, diagnosis, and therapeutic management of granuloma annulare: an update","volume":"14","author":"Thornsberry","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.12.028_bib5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s004030000150","article-title":"Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare","volume":"292","author":"Fayyazi","year":"2000","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/1523-1747.ep12499857","article-title":"Collagen synthesis in granuloma annulare","volume":"98","author":"Kallioinen","year":"1992","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.12.028_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/11311040-000000000-00000","article-title":"Anti-tumor necrosis factor-\u03b1 treatment with infliximab for disseminated granuloma annulare","volume":"11","author":"Murdaca","year":"2010","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.028_bib8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2133.2005.06371.x","article-title":"Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab","volume":"152","author":"Hertl","year":"2005","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.028_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jaad.2015.09.015","article-title":"Treatment of recalcitrant granuloma annulare (GA) with adalimumab: a single-center, observational study","volume":"74","author":"Min","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.028_bib10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archdermatol.2009.92","article-title":"Efficacy of adalimumab in the treatment of generalized granuloma annulare in monozygotic twins carrying the 8.1 ancestral haplotype","volume":"145","author":"Knoell","year":"2009","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-4632.2010.04348.x","article-title":"Generalized interstitial granuloma annulare\u2014response to adalimumab","volume":"49","author":"Werchau","year":"2010","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.028_bib12","first-page":"169","article-title":"Successful treatment of disseminated granuloma annulare with adalimumab","volume":"8","author":"Rosmarin","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.028_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/ced.12598","article-title":"Successful treatment of generalized granuloma annulare with adalimumab","volume":"40","author":"Mahmood","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2019.12.028_bib14","first-page":"1466","article-title":"Treatment of recalcitrant generalized granuloma annulare with adalimumab","volume":"10","author":"Torres","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.12.028_bib15","first-page":"42","article-title":"Treatment of widespread granuloma annulare with adalimumab: a case report","volume":"4","author":"Kozic","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2019.12.028_bib16","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.jid.2019.04.008","article-title":"Major differences in expression of inflammatory pathways in skin from different body sites of healthy individuals","volume":"139","author":"Del Duca","year":"2019","journal-title":"J Invest Dematol"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.028_bib17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in\u00a0African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.028_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.028_bib19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.028_bib20","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2018.06.029","article-title":"An integrated model\u00a0of\u00a0alopecia areata biomarkers highlights both TH1 and TH2\u00a0upregulation","volume":"142","author":"Song","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.028_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cea.12875","article-title":"Human basophils are a source of - and are differentially activated by - IL-31","volume":"47","author":"Raap","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.jaad.2019.12.028_bib23","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.4049\/jimmunol.0900712","article-title":"Antimicrobial peptides human \u03b2-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells","volume":"184","author":"Niyonsaba","year":"2010","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.028_bib24","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jid.2018.03.567","article-title":"ASN002 a dual oral inhibitor of JAK\/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients","volume":"138","author":"Guttman-Yassky","year":"2018","journal-title":"J Invest Dematol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Guttman-Yassky","year":"2018","journal-title":"Exp Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2019.12.028_bib26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2000.105948","article-title":"Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions","volume":"42","author":"Oh","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.028_bib27","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/09546634.2017.1395796","article-title":"Review of IL-17 inhibitors for psoriasis","volume":"29","author":"Amin","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2019.12.028_bib29","doi-asserted-by":"crossref","first-page":"105841","DOI":"10.1016\/j.intimp.2019.105841","article-title":"Treatment of plaque psoriasis with IL-23p19 blockers: a systematic review and meta-analysis","volume":"75","author":"Xu","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.028_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic\u00a0dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2019.12.028_bib31","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.028_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.028_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.028_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"10.1016\/j.jaad.2019.12.028_bib35","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.028_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2019.12.028_bib37","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.028_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2b randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"9625","key":"10.1016\/j.jaad.2019.12.028_bib39","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of\u00a0ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.028_bib40","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.jaad.2017.12.019","article-title":"Emerging therapies for atopic dermatitis: JAK inhibitors","volume":"78","author":"Cotter","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2019.12.028_bib41","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.028_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK inhibitors for atopic dermatitis: an update","volume":"20","author":"He","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral JAK\/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2019.12.028_bib45","doi-asserted-by":"crossref","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.028_bib46","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI117408","article-title":"Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis","volume":"94","author":"Hamid","year":"1994","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.028_bib47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI21060","article-title":"New insights into atopic dermatitis","volume":"113","author":"Leung","year":"2004","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.028_bib48","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic\u00a0dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.028_bib49","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219333055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219333055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:56:26Z","timestamp":1759272986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219333055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0190962219333055"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.12.028","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}